Revolade

(eltrombopag olamine) Novartis

Composition:

• Available in film-coated tablet with each contains eltrombopag olamine equivalents to 25 mg of eltrombopag

Indications:

• For the treatment of chronic immune thrombocytopaenia (ITP):
• in paediatric patients who have failed other treatments and either need an increased platelet concentration for a planned procedure or are at a high risk of bleeding
• in adult patients who have had an inadequate response or are intolerant to corticosteroids and immunoglobulins

• For the treatment of thrombocytopenia:
• in adult patients with chronic hepatitis C to allow the initiation and maintenance of interferon-based therapy

• For the treatment of severe aplastic anaemia (SAA):
•  in combination with standard immunosuppressive therapy for the first-line treatment in adult and paediatric patients 2 years and older
• in adult patients who have had an insufficient response to immunosuppressive therapy

Drug information including formulation, indication, administration and/or presentation updated, registered or launched in Hong Kong within one year prior to the date written is regarded as new in The Pace.

The information in The Pace is provided as a courtesy service to our readers and is intended for medical professional reference only. Please peruse the latest local prescription information prior to prescription.